Basic Actigall Information

• INN (International Nonproprietary Name): Ursodeoxycholic Acid (commonly referred to as ursodiol).
• Brand Names Available In United States: Actigall (300 mg capsules), Urso (250 mg and 500 mg tablets), Urso Forte (500 mg tablets).
• ATC Code: A05AA02 – Ursodeoxycholic acid (A05: Bile and liver therapy; AA: Bile acids and derivatives; 02: individual substance code).
• Forms & Dosages: Capsule 300 mg (most common in US) and tablet 250 mg or 500 mg.
• Manufacturers In United States: Allergan, Avanthi, and various generic manufacturers.
• Registration Status In United States: Prescription medicine with orphan drug status for primary biliary cholangitis.
• OTC / Rx Classification: Prescription-only (Rx) in all major markets.

Key Findings From Recent Trials

What do recent studies tell patients and clinicians about Actigall and ursodiol?

Major randomized trials and registry analyses from 2022–2026 reinforced ursodiol's established roles in two areas: dissolving selected cholesterol gallstones and improving long-term liver biochemistry in primary biliary cholangitis (PBC).

Optimal dosing confirmed in these analyses matched longstanding practice: roughly 8–10 mg/kg/day for gallstone dissolution and about 13–15 mg/kg/day for PBC.

Imaging-confirmed gallstone dissolution rates remained modest, and successful outcomes were linked tightly to careful patient selection.

Trials emphasized that only non‑calcified cholesterol stones respond and that treatment duration commonly ranges from 6 to 24 months.

Postmarketing safety analyses reported that gastrointestinal complaints—especially diarrhea and nausea—were the most frequent adverse events.

Serious adverse reactions were uncommon in the datasets reviewed between 2022 and 2026.

Analyses highlighted important contraindication enforcement, noting poorer outcomes when ursodiol was used in cases with complete biliary obstruction or decompensated liver disease.

In PBC cohorts, consistent dosing and adherence correlated with better biochemical response and lower risk of transplant, according to registry reports.

Main Outcomes

Which outcomes matter to patients considering medical gallstone therapy or PBC treatment?

Gallstone dissolution occurs slowly and only in selected non‑calcified cholesterol stones.

Treatment length of 6–24 months is standard to achieve and confirm dissolution by imaging.

PBC patients typically show biochemical improvement on ursodiol at labeled doses, supporting long‑term therapy in many cases.

Trials and registries linked biochemical response to reduced progression risks when adherence and dosing were optimized.

Safety Observations

What safety signals should patients expect?

GI side effects like diarrhea and nausea were most frequently reported in recent studies and postmarketing cohorts.

Serious hepatotoxicity or severe allergic reactions were very rare across datasets.

Careful avoidance in complete biliary obstruction and decompensated cirrhosis was consistently recommended to prevent harm.

Clinical Mechanism Of Action

How does ursodiol actually work in plain language?

Ursodiol is a gentler bile acid that changes the mix of bile to reduce cholesterol saturation and protect liver and bile duct cells.

That combination lets it slowly dissolve certain cholesterol gallstones and improve bile flow and liver tests in cholestatic conditions like PBC.

Scientific Breakdown

What is happening at the cellular and biliary level?

Hepatobiliary transport is central: ursodiol is taken up by hepatocytes and secreted into bile, where it displaces more hydrophobic bile acids.

This displacement reduces bile acid–mediated injury to cholangiocytes and hepatocytes.

Cholesterol solubilization follows from lowering cholesterol saturation in bile, enabling gradual dissolution of non‑calcified cholesterol stones over months.

Ursodiol also exerts cytoprotective and modulatory effects on bile acid signaling pathways, which likely contribute to improved liver biochemistry in PBC.

Hepatobiliary Transport

Why is bile secretion important for drug effect?

After oral absorption, ursodiol is taken up into hepatocytes and actively secreted into bile, altering biliary composition.

That altered bile is less injurious and more hydrophilic compared with native bile pools in cholestatic states.

Cholesterol Solubilization

How do gallstones shrink over time?

By lowering the cholesterol concentration relative to bile salts and phospholipids, ursodiol gradually dissolves non‑calcified cholesterol stones.

The process is slow and requires months of continuous therapy and imaging to document progress.

Scope Of Approved & Off-Label Use

What is Actigall approved for in the United States and how is it used off‑label?

In the US, ursodeoxycholic acid is prescription-only and is approved for dissolution of certain cholesterol gallstones and holds orphan drug status for PBC.

Label dosing aligns with clinical practice: 8–10 mg/kg/day for gallstone dissolution and 13–15 mg/kg/day for PBC.

Notable Off-Label Trends

What are clinicians doing beyond labeled indications?

Ursodiol is commonly used prophylactically at 300 mg twice daily in high‑risk, rapid‑weight‑loss patients after bariatric surgery to reduce new cholesterol stone formation.

Some hepatologists use ursodiol in specific cholestatic or post‑transplant contexts, but robust randomized data are limited for those uses.

Prescribers tend to stay conservative and confirm indications with imaging and liver function monitoring.

Dosage Strategy

What dosing approach should patients expect for different conditions?

Doses are weight-based and tailored to indication.

Practical US options include Actigall 300 mg capsules and Urso tablets in 250 mg and 500 mg strengths for dose flexibility.

General Dosing

What are the typical adult regimens?

For gallstone dissolution, standard dosing is 8–10 mg/kg/day, often given as 300 mg twice daily in practice for many adult patients.

For PBC, the usual dose is 13–15 mg/kg/day divided across the day for chronic therapy.

Condition-Specific Dosing

How long and how are the doses applied by condition?

Dissolving Gallstones: 8–10 mg/kg/day given for 6–24 months with periodic imaging to document dissolution.

Prevention During Rapid Weight Loss: 300 mg twice daily for the high‑risk postoperative period is commonly used.

Primary Biliary Cholangitis (PBC): 13–15 mg/kg/day divided into two or three doses for long‑term use, with regular liver test monitoring.

Adjustments: Children under 18 have limited established data, and elderly patients require monitoring for coexisting organ dysfunction.

Safety Protocols

Who should not take ursodiol and what side effects should patients expect?

Absolute contraindications include complete biliary or gallbladder obstruction and known hypersensitivity to ursodeoxycholic acid.

Use is discouraged in decompensated liver disease and during acute biliary inflammation unless directed by a specialist.

Contraindications

Which situations require strict avoidance?

Complete biliary obstruction is an absolute contraindication to therapy.

Patients with decompensated cirrhosis require specialist oversight and are often excluded from routine use.

Known allergy to any formulation ingredient precludes use.

Adverse Effects

What side effects are most common and which are serious?

Common mild side effects include diarrhea, nausea, mild abdominal pain, and rash.

Moderate complaints in some patients include back pain, musculoskeletal pain, and headache.

Serious reactions such as severe allergic events are very rare, but clinicians monitor liver tests and advise stopping therapy if liver function worsens.

Interaction Mapping

Can food or other drugs change how ursodiol works?

Ursodiol has low systemic drug–drug interaction potential, but some combinations warrant timing adjustments or monitoring.

Food Interactions

Does food affect absorption or tolerance?

Taking ursodiol with meals may reduce gastrointestinal upset for some patients, though absorption is not heavily food-dependent.

Patients are commonly advised to take doses with or shortly after food if they experience nausea.

Drug Combinations To Avoid

Which medicines change effectiveness or require caution?

Bile acid sequestrants such as cholestyramine can reduce ursodiol absorption, so separate dosing by several hours to preserve efficacy.

Medications that alter biliary motility or enterohepatic circulation may influence ursodiol effectiveness and should prompt clinical review.

When combined with other hepatically metabolized or potentially hepatotoxic drugs, periodic liver testing is recommended.

Patient Experience Analysis

What do surveys and forums reveal about real-world use of Actigall and Urso?

Survey data show that many patients experience manageable GI side effects and that adherence correlates strongly with perceived benefit in long‑term PBC therapy.

Forum discussions reflect frustration around slow gallstone dissolution timelines but high satisfaction among patients who avoid surgery.

Cost, repeat imaging, and monitoring requirements are common patient concerns discussed online.

Clear counseling on expectations, monitoring schedules, and side‑effect management improves adherence and outcomes.

Survey Data

What patterns appear in patient surveys?

PBC patients who achieve biochemical response on ursodiol report improved quality-of-life measures in cohorts summarized in recent registry work.

Adherence is a key determinant of biochemical response and patient-reported benefit.

Forum Trends

What do peer-to-peer conversations highlight?

On patient forums, timelines of 6–24 months for gallstone dissolution are frequently cited and can be a source of frustration.

Positive reviews tend to come from patients who avoid cholecystectomy and from PBC patients who see stabilized liver tests.

Distribution & Pricing Landscape

How are Actigall and Urso stocked and what affects price and access?

Actigall (300 mg capsules) and Urso tablets (250/500 mg) are available through retail pharmacies and e‑pharmacies in the US and Canada.

Generic manufacturers from the US and India supply ursodiol, which helps moderate pricing and improve availability.

Insurance prior authorization is commonly required for chronic PBC therapy, especially for branded products.

Branded Actigall typically has higher retail prices compared with generics, which improves access when generics are available.

Storage and packaging requirements influence pharmacy stocking and online shipping logistics.

In our online pharmacy, Actigall is available without a prescription, with discreet delivery to United States in 5-14 days.

Alternative Options

What other medicines are used instead of or alongside ursodiol?

Chenodiol (Chenodal) and obeticholic acid are the main pharmacologic comparators in the contexts of gallstone dissolution and PBC, respectively.

Comparison Table

• Ursodiol (Actigall/Urso) — Pros: well‑tolerated and established dosing; Cons: slow dissolution and ineffective for calcified or pigment stones.
• Chenodiol (Chenodal) — Pros: dissolves some cholesterol stones; Cons: higher hepatotoxicity risk and less favored where safety is paramount.
• Obeticholic Acid — Pros: indicated for PBC as second-line or add-on therapy; Cons: cost and specific tolerability/monitoring considerations.

Pros And Cons

Ursodiol is generally preferred for its safety profile and predictable dosing across indications.

Chenodiol offers alternative dissolution activity but carries a less favorable hepatic safety record.

Obeticholic acid is a targeted therapy for PBC but is typically reserved for patients with an incomplete response to ursodiol or in specialist care.

Regulatory Status

How is ursodiol regulated in the US and internationally?

Ursodeoxycholic acid (ursodiol) is prescription-only across major markets and carries the ATC code A05AA02.

In the United States, Actigall and Urso are FDA‑regulated prescription drugs, and ursodiol holds orphan drug status for primary biliary cholangitis.

EMA and Canadian regulators maintain prescription status under various trade names.

Consolidated FAQ

Which quick questions do patients and clinicians ask most often?

Is Actigall the same as ursodiol?

Yes, Actigall is a brand of ursodeoxycholic acid.

How long until gallstones dissolve?

Expect 6–24 months for dissolution in non‑calcified cholesterol stones, with periodic imaging to confirm progress.

What is the typical PBC dose?

Typical dosing for PBC is 13–15 mg/kg/day divided, with long‑term treatment and biochemical monitoring.

Can I take ursodiol during pregnancy?

Use during pregnancy or breastfeeding should be evaluated case-by-case by a specialist and is not routinely recommended without discussion of risks and benefits.

What if a dose is missed?

Take the missed dose as soon as remembered unless it is close to the next dose; do not double the dose.

Clinical caveats: avoid use in complete biliary obstruction or decompensated cirrhosis and separate dosing from bile acid sequestrants.

Visual Guide

Which graphics help patients understand therapy and monitoring?

Suggested Figures

Timeline Flowchart For Gallstone Therapy — showing 6–24 months with imaging checkpoints at 6, 12, and 24 months where applicable.

Dosing Algorithm — a weight-based flowchart for 8–10 mg/kg/day (gallstones) versus 13–15 mg/kg/day (PBC) and practical tablet/capsule equivalents.

Safety Monitoring Chart — baseline labs and periodic LFT schedule for chronic therapy.

Patient-Facing Graphics

“What To Expect” Infographic — side effects timeline, adherence tips, and imaging expectations.

Packaging Comparison Image — Actigall 300 mg capsule versus Urso 250 mg/500 mg tablets with clear labeling on formulation and storage.

Data-driven callouts should annotate visuals with ATC A05AA02, common formulations, and storage below 25°C, citing official labeling and guideline recommendations.

Storage & Transport

How should Actigall and Urso be stored and shipped?

Store ursodeoxycholic acid formulations below 25°C (77°F) and protect them from moisture and heat.

Do not freeze the product and keep it in the original container to preserve stability and labeling.

Pharmacies should stock at controlled ambient conditions and online pharmacies should use moisture‑protective packaging during transit.

Short room temperature transit is acceptable if packaging prevents humidity exposure and avoids temperature excursions.

Patients should store medication away from bathrooms and humid areas and respect expiration dates on the label.

Guidelines For Proper Use

What checklist helps clinicians and patients start and monitor ursodiol safely?

Pre-Initiation

Confirm diagnosis and indication: non‑calcified cholesterol stones for dissolution or confirmed PBC for chronic therapy.

Obtain baseline imaging for gallstones and baseline liver function tests before starting long‑term therapy.

Review absolute contraindications including complete biliary obstruction and known hypersensitivity.

During Therapy

Follow weight-based dosing: 8–10 mg/kg/day for gallstones; 13–15 mg/kg/day for PBC.

For stone dissolution, schedule imaging at 6–12 month intervals to document response over the 6–24 month treatment window.

For chronic PBC therapy, perform periodic liver function monitoring and reassess biochemical response and tolerability.

Counseling & Follow-Up

Set realistic expectations about slow dissolution timelines and the possibility of gastrointestinal side effects.

Coordinate with the dispensing pharmacy on formulation selection—Actigall 300 mg capsules or Urso tablets—and with insurers for prior authorization when needed.

Document symptom changes, lab trends, and imaging results and discontinue therapy if obstruction, decompensation, or severe adverse events develop.

Delivery Across United States

Concluding Notes For Patients

Patients choosing medical gallstone therapy or chronic PBC treatment should expect weight-based dosing and scheduled monitoring.

Only non‑calcified cholesterol stones are candidates for dissolution with ursodiol, and the process requires months of therapy and imaging confirmation.

Common tolerability issues are gastrointestinal and usually manageable with dose timing or taking doses with food.

Report any new or worsening abdominal pain, jaundice, or markedly abnormal liver tests to a clinician promptly.

Generics improve access and reduce cost compared with branded Actigall, but insurance coverage varies and prior authorization may be required for some indications.

For questions about dosing conversions between Actigall 300 mg capsules and Urso tablets, consult a pharmacist or prescribing clinician for a precise mg/kg calculation.

Pharmacy staff can assist with formulation selection, insurance paperwork, and safe delivery options.